

Souhrnná statistika - kvantitativní výsledky

(Skupiny: princip měření, výrobce reagentie)

Filtr: Slovensko, minimální četnost skupin n = 5

Cyklus EHK: E12/20 - Endokrinologie 1

Stop termín: 05.05.2020

| | | |
|---|---|---------------------------------------|
| RoM = robustní průměr | AV = vztažná hodnota | Dmax = přijatelný rozdíl v procentech |
| SD = směrodatná odchylka | CRV = certifikovaná referenční hodnota | LL = dolní mez |
| CV = variační koeficient | RV = referenční hodnota | UL = horní mez |
| Ntot = celkový počet účastníků | CVE = konsenzus expertů | Neva = počet hodnocených účastníků |
| Nout = počet výsledků vyloučených před výpočtem | CVP = konsenzus všech účastníků | Nsuc = počet úspěšných účastníků |
| | CVPG = konsenzus skupin účastníků | Srel = relativní úspěšnost |
| | U _{AV} = rozšířená nejistota vztažné hodnoty (k = 2) | |

| Zkouška | [jednotka] | Srovnatelnost | | | | | | | | | | Ná vaznost | | | | | | | | | | | | | |
|--|------------|---------------|------|--------|------------------|------------------|--------------------------------------|-----------------|------------------|-----|------|------------------|------------------|------------------|----|-----------------|------------------|-------|-------|------------------|------------------|------------------|------|---|------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | | | |
| (121) T3 celkový | | | | | 2 | | | | | | | | | 2 | 2 | 100% | | | | | 2 | 1 | 50% | | |
| Vzorky a skupiny | [nmol/L] | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 5,28 | 0,38 | 7,2 | 2 | | | | | | | | | 2 | 2 | 100% | CRV | 6,4 | 0,085 | 20% | 5,12 | 7,68 | 2 | 1 | 50% |
| Ostatní | | | | | 2 | 0 | | | | | | | | 2 | | | | | | | | | 2 | | |
| | | | | | | | 1x 4/1, 1x 4/29 | | | | | | | | | | 1x 4/1, 1x 4/29 | | | | | | | | |
| Vzorek B | | 1,65 | 0,04 | 2,7 | 2 | | | | | | | | | 2 | 2 | 100% | CRV | 2,049 | 0,020 | 20% | 1,63 | 2,46 | 2 | 1 | 50% |
| Ostatní | | | | | 2 | 0 | | | | | | | | 2 | | | | | | | | | 2 | | |
| | | | | | | | 1x 4/1, 1x 4/29 | | | | | | | | | | 1x 4/1, 1x 4/29 | | | | | | | | |
| (122) T4 celkový | | | | | 2 | | | | | | | | | 2 | 2 | 100% | | | | | 2 | 2 | 100% | | |
| Vzorky a skupiny | [nmol/L] | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 198 | 1,8 | 0,91 | 2 | | | | | | | | | 2 | 2 | 100% | CRV | 201,3 | 2,3 | 17% | 167 | 236 | 2 | 2 | 100% |
| Ostatní | | | | | 2 | 0 | | | | | | | | 2 | | | | | | | | | 2 | | |
| | | | | | | | 1x 4/1, 1x 4/29 | | | | | | | | | | 1x 4/1, 1x 4/29 | | | | | | | | |
| Vzorek B | | 230 | 10 | 4,4 | 2 | | | | | | | | | 2 | 2 | 100% | CRV | 261,2 | 2,9 | 17% | 216 | 306 | 2 | 2 | 100% |
| Ostatní | | | | | 2 | 0 | | | | | | | | 2 | | | | | | | | | 2 | | |
| | | | | | | | 1x 4/1, 1x 4/29 | | | | | | | | | | 1x 4/1, 1x 4/29 | | | | | | | | |
| (123) TSH | | | | | 29 | | | | | | | | | 29 | 29 | 100% | | | | | 0 | | | | |
| Vzorky a skupiny | [mU/L] | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 6,34 | 0,55 | 8,6 | 29 | | | | | | | | | 29 | 29 | 100% | | | | | 0 | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 5,46 | 0,04 | 0,79 | 5 | 0 | CVPG | 5,7 | 0,052 | 14% | 4,9 | 6,5 | | 5 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 6,20 | 0,28 | 4,6 | 7 | 0 | CVPG | 6,12 | 0,061 | 14% | 5,26 | 6,98 | | 7 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 6,60 | 0,26 | 3,9 | 12 | 0 | CVPG | 6,53 | 0,024 | 14% | 5,61 | 7,45 | | 12 | | | | | | | | | | | |
| Ostatní | | | | | 5 | 0 | | | | | | | | 5 | | | | | | | | | | | |
| | | | | | | | 1x 3/25, 1x 4/29, 1x 4/149, 2x 4/179 | | | | | | | | | | | | | | | | | | |
| Vzorek B | | 5,06 | 0,52 | 10 | 29 | | | | | | | | | 29 | 29 | 100% | | | | | 0 | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 3,98 | 0,02 | 0,56 | 5 | 0 | CVPG | 4,1 | 0,037 | 14% | 3,52 | 4,68 | | 5 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 5,00 | 0,23 | 4,7 | 7 | 0 | CVPG | 4,86 | 0,042 | 14% | 4,17 | 5,55 | | 7 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 5,44 | 0,22 | 4,0 | 12 | 0 | CVPG | 5,44 | 0,018 | 14% | 4,67 | 6,21 | | 12 | | | | | | | | | | | |
| Ostatní | | | | | 5 | 0 | | | | | | | | 5 | | | | | | | | | | | |
| | | | | | | | 1x 3/25, 1x 4/29, 1x 4/149, 2x 4/179 | | | | | | | | | | | | | | | | | | |
| (124) T4 volný | | | | | 28 | | | | | | | | | 28 | 27 | 96% | | | | | 0 | | | | |
| Vzorky a skupiny | [pmol/L] | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 41,7 | 7,6 | 18 | 28 | | | | | | | | | 28 | 27 | 96% | | | | | 0 | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 30,4 | 0,81 | 2,7 | 5 | 0 | CVPG | 30,9 | 0,33 | 13% | 26,8 | 35 | | 5 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 42,9 | 1,8 | 4,2 | 7 | 0 | CVPG | 42,7 | 0,58 | 13% | 37,1 | 48,3 | | 7 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 47,0 | 1,2 | 2,5 | 12 | 0 | CVPG | 47,3 | 0,24 | 13% | 41,1 | 53,5 | | 12 | | | | | | | | | | | |

Souhrnná statistika - kvantitativní výsledky

(Skupiny: princip měření, výrobce reagentie)

Filtr: Slovensko, minimální četnost skupin n = 5

Cyklus EHK: E12/20 - Endokrinologie 1

Stop termín: 05.05.2020

| Zkouška | [jednotka] | Srovnatelnost | | | | | | Návaznost | | | | | | | | | | | | | | | | |
|--|------------|---------------|------|--------|------------------|------------------|------|-----------------|------------------|-----|------|------------------|------------------|------------------|-----|-----------------|------------------|-----|-----|------------------|------------------|------------------|----|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | | |
| (124) T4 volný | | | | | 28 | | | | | | | 28 | 27 | 96% | | | | | | | | | 0 | |
| Vzorky a skupiny | [pmol/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 41,7 | 7,6 | 18 | 28 | | | | | | | 28 | 27 | 96% | | | | | | | | | 0 | |
| Ostatní | | | | | 4 | 0 | | | | | | 4 | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek B | | 54,2 | 13 | 24 | 28 | | | | | | | 28 | 27 | 96% | | | | | | | | | 0 | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 36,9 | 2,3 | 6,3 | 5 | 0 | CVPG | 38,2 | 0,53 | 13% | 33,2 | 43,2 | | | 5 | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 50,8 | 1,3 | 2,5 | 7 | 0 | CVPG | 50,8 | 0,69 | 13% | 44,1 | 57,5 | | | 7 | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 64,9 | 2,4 | 3,7 | 12 | 0 | CVPG | 65 | 0,38 | 13% | 56,5 | 73,5 | | | 12 | | | | | | | | | |
| Ostatní | | | | | 4 | 0 | | | | | | | | | 4 | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| (125) T3 volný | | | | | 19 | | | | | | | 19 | 19 | 100% | | | | | | | | | 0 | |
| Vzorky a skupiny | [pmol/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 25,4 | 4,9 | 19 | 19 | | | | | | | 19 | 19 | 100% | | | | | | | | | 0 | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 20,8 | 1,6 | 7,6 | 5 | 0 | CVPG | 20,2 | 0,27 | 15% | 17,1 | 23,3 | | | 5 | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 29,3 | 0,54 | 1,8 | 9 | 0 | CVPG | 29,5 | 0,087 | 15% | 25 | 34 | | | 9 | | | | | | | | | |
| Ostatní | | | | | 5 | 0 | | | | | | | | | 5 | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek B | | 7,12 | 0,96 | 14 | 19 | | | | | | | 19 | 19 | 100% | | | | | | | | | 0 | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 6,50 | 0,30 | 4,6 | 5 | 0 | CVPG | 6,25 | 0,083 | 15% | 5,31 | 7,19 | | | 5 | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 7,69 | 0,28 | 3,7 | 9 | 0 | CVPG | 7,61 | 0,030 | 15% | 6,46 | 8,76 | | | 9 | | | | | | | | | |
| Ostatní | | | | | 5 | 0 | | | | | | | | | 5 | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| (200) Feritin | | | | | 22 | | | | | | | 21 | 16 | 76% | | | | | | | | | 0 | |
| Vzorky a skupiny | [µg/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 108 | 19 | 18 | 22 | | | | | | | 21 | 21 | 100% | | | | | | | | | 0 | |
| Ostatní | | | | | 22 | 0 | | | | | | 21 | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek B | | 17,5 | 4,6 | 26 | 22 | | | | | | | 21 | 16 | 76% | | | | | | | | | 0 | |
| Ostatní | | | | | 22 | 0 | | | | | | 21 | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| (301) Kortizol | | | | | 13 | | | | | | | 13 | 11 | 85% | | | | | | | | | 13 | |
| Vzorky a skupiny | [nmol/L] | | | | | | | | | | | | | | | | | | | | | | 10 | |
| Vzorek A | | 1030 | 170 | 17 | 13 | | | | | | | 13 | 11 | 85% | GRV | 1029 | 11 | 22% | 802 | 1260 | | 13 | 10 | 77% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 1030 | 79 | 7,7 | 5 | 0 | CVPG | 1000 | 27 | 16% | 840 | 1160 | | | 5 | | | | | | | 5 | | |
| Ostatní | | | | | 8 | 0 | | | | | | | | | 8 | | | | | | | | 8 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek B | | 277 | 41 | 15 | 13 | | | | | | | 13 | 12 | 92% | GRV | 305,9 | 3,7 | 22% | 238 | 374 | | 13 | 11 | 85% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 244 | 0,89 | 0,36 | 5 | 0 | CVPG | 247 | 6,4 | 16% | 207 | 287 | | | 5 | | | | | | | 5 | | |
| Ostatní | | | | | 8 | 0 | | | | | | | | | 8 | | | | | | | | 8 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |

Filtr: Slovensko, minimální četnost skupin n = 5

Cyklus EHK: E12/20 - Endokrinologie 1

Stop termín: 05.05.2020

| Zkouška | [jednotka] | Srovnatelnost | | | | | | | | | | Ná vaznost | | | | | | | | | | | | |
|--|------------|---------------|------|--------|------------------|------------------|------|-------------------------------------|------------------|-----|------|------------------|------------------|------------------|-----|-----------------|------------------|-----|------|------------------|------------------|------------------|------|--|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | | |
| (302) Estradiol | [pmol/L] | | | | 16 | | | | | | | 16 | 16 | 100% | | | | | | | 0 | | | |
| Vzorky a skupiny | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 668 | 36 | 5,3 | 16 | | | | | | | 16 | 16 | 100% | | | | | | | 0 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 691 | 30 | 4,3 | 6 | 0 | CVPG | 669 | 10 | 22% | 521 | 817 | 6 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 644 | 27 | 4,2 | 6 | 0 | CVPG | 670 | 4,9 | 22% | 522 | 818 | 6 | | | | | | | | | | | |
| Ostatní | | | | | 4 | 0 | | | | | | | 4 | | | | | | | | | | | |
| | | | | | | | | 1x 3/25, 2x 4/1, 1x 4/179 | | | | | | | | | | | | | | | | |
| Vzorek B | | 1480 | 140 | 9,8 | 16 | | | | | | | 16 | 16 | 100% | | | | | | | 0 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 1570 | 67 | 4,3 | 6 | 0 | CVPG | 1520 | 22 | 22% | 1180 | 1860 | 6 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 1500 | 64 | 4,3 | 6 | 0 | CVPG | 1490 | 9,6 | 22% | 1160 | 1820 | 6 | | | | | | | | | | | |
| Ostatní | | | | | 4 | 0 | | | | | | | 4 | | | | | | | | | | | |
| | | | | | | | | 1x 3/25, 2x 4/1, 1x 4/179 | | | | | | | | | | | | | | | | |
| (303) Aldosteron | [nmol/L] | | | | 3 | | | | | | | 2 | 2 | 100% | | | | | | | 0 | | | |
| Vzorky a skupiny | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 1,18 | 0,07 | 6,5 | 3 | | | | | | | 2 | 2 | 100% | | | | | | | 0 | | | |
| Ostatní | | | | | 3 | 0 | | | | | | | 2 | | | | | | | | | | | |
| | | | | | | | | 1x 1/36, 1x 1/218, 1x 2/66 | | | | | | | | | | | | | | | | |
| Vzorek B | | 1,54 | 0,32 | 21 | 3 | | | | | | | 2 | 2 | 100% | | | | | | | 0 | | | |
| Ostatní | | | | | 3 | 0 | | | | | | | 2 | | | | | | | | | | | |
| | | | | | | | | 1x 1/36, 1x 1/218, 1x 2/66 | | | | | | | | | | | | | | | | |
| (304) Progesteron | [nmol/L] | | | | 17 | | | | | | | 17 | 16 | 94% | | | | | | | 17 | 13 | 76% | |
| Vzorky a skupiny | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 26,2 | 6,7 | 26 | 17 | | | | | | | 17 | 16 | 94% | CRV | 26,35 | 0,26 | 26% | 19,4 | 33,3 | 17 | 13 | 76% | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 22,1 | 1,5 | 6,8 | 5 | 0 | CVPG | 22,3 | 0,54 | 20% | 17,8 | 26,8 | 5 | | | | | | | | 5 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 31,7 | 0,67 | 2,1 | 6 | 0 | CVPG | 31 | 0,23 | 20% | 24,8 | 37,2 | 6 | | | | | | | | 6 | | | |
| Ostatní | | | | | 6 | 0 | | | | | | | 6 | | | | | | | | | 6 | | |
| | | | | | | | | 1x 3/25, 3x 4/1, 2x 4/179 | | | | | | | | | | | | | | | | |
| Vzorek B | | 11,8 | 2,4 | 20 | 17 | | | | | | | 17 | 16 | 94% | CRV | 12,23 | 0,13 | 26% | 9,05 | 15,5 | 17 | 15 | 88% | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 10,1 | 0,36 | 3,5 | 5 | 0 | CVPG | 10,8 | 0,34 | 20% | 8,64 | 13 | 5 | | | | | | | | 5 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 13,8 | 0,61 | 4,4 | 6 | 0 | CVPG | 13,6 | 0,11 | 20% | 10,8 | 16,4 | 6 | | | | | | | | 6 | | | |
| Ostatní | | | | | 6 | 0 | | | | | | | 6 | | | | | | | | | 6 | | |
| | | | | | | | | 1x 3/25, 3x 4/1, 2x 4/179 | | | | | | | | | | | | | | | | |
| (305) Testosteron | [nmol/L] | | | | 19 | | | | | | | 18 | 17 | 94% | | | | | | | 19 | 19 | 100% | |
| Vzorky a skupiny | | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 5,49 | 0,46 | 8,4 | 19 | | | | | | | 18 | 17 | 94% | CRV | 5,433 | 0,077 | 30% | 3,8 | 7,07 | 19 | 19 | 100% | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 5,47 | 0,79 | 14 | 7 | 0 | CVPG | 5,62 | 0,099 | 22% | 4,38 | 6,86 | 7 | | | | | | | | 7 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 5,55 | 0,09 | 1,7 | 8 | 0 | CVPG | 5,63 | 0,045 | 22% | 4,39 | 6,87 | 8 | | | | | | | | 8 | | | |
| Ostatní | | | | | 4 | 0 | | | | | | | 3 | | | | | | | | | 4 | | |
| | | | | | | | | 1x 3/25, 1x 4/1, 1x 4/149, 1x 4/179 | | | | | | | | | | | | | | | | |
| Vzorek B | | 4,16 | 0,31 | 7,4 | 19 | | | | | | | 18 | 18 | 100% | CRV | 4,615 | 0,054 | 30% | 3,23 | 6 | 19 | 19 | 100% | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 4,23 | 0,41 | 9,6 | 7 | 0 | CVPG | 4,24 | 0,062 | 22% | 3,3 | 5,18 | 7 | | | | | | | | 7 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 4,19 | 0,13 | 3,0 | 8 | 0 | CVPG | 4,32 | 0,037 | 22% | 3,36 | 5,28 | 8 | | | | | | | | 8 | | | |

Souhrnná statistika - kvantitativní výsledky

(Skupiny: princip měření, výrobce reagentie)

Filtr: Slovensko, minimální četnost skupin n = 5

Cyklus EHK: E12/20 - Endokrinologie 1

Stop termín: 05.05.2020

| Zkouška | [jednotka] | Srovnatelnost | | | | | | Návaznost | | | | | | | | | | | | | | | |
|------------------------------------|------------|---------------|------|--------|------------------|------------------|------|-----------------|------------------|-----|------|------------------|------------------|------------------|-------|-----------------|------------------|------|------|------------------|------------------|------------------|------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (305) Testosteron | [nmol/L] | | | | 19 | | | | | | | 18 | 17 | 94% | | | | | | | 19 | 19 | 100% |
| Vzorky a skupiny | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek B | | 4,16 | 0,31 | 7,4 | 19 | | | | | | 18 | 18 | 100% | CRV | 4,615 | 0,054 | 30% | 3,23 | 6 | 19 | 19 | 100% | |
| Ostatní | | | | | 4 | 0 | | | | | 3 | | | | | | | | | 4 | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| (306) 17-OH-progesteron | [nmol/L] | | | | 4 | | | | | | 3 | 3 | 100% | | | | | | | 4 | 3 | 75% | |
| Vzorky a skupiny | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 14,1 | 10 | 73 | 4 | | | | | | 3 | 3 | 100% | CRV | 7,113 | 0,071 | 44% | 3,98 | 10,3 | 4 | 3 | 75% | |
| Ostatní | | | | | 4 | 0 | | | | | 3 | | | | | | | | | 4 | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek B | | 6,74 | 4,0 | 59 | 4 | | | | | | 3 | 3 | 100% | CRV | 3,219 | 0,032 ± 2,641 | 0,579 | 5,86 | 4 | 3 | 75% | | |
| Ostatní | | | | | 4 | 0 | | | | | 3 | | | | | | | | | 4 | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| (307) DHEA-sulfát | [µmol/L] | | | | 10 | | | | | | 10 | 8 | 80% | | | | | | | 0 | | | |
| Vzorky a skupiny | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek A | | 13,0 | 2,1 | 16 | 10 | | | | | | 10 | 9 | 90% | | | | | | | 0 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 14,7 | 0,17 | 1,2 | 5 | 0 | CVPG | 14,1 | 0,15 | 21% | 11,1 | 17,1 | 5 | | | | | | | | | | |
| (60) Roche | | | | | | | | | | | | | | | | | | | | | | | |
| Ostatní | | | | | 5 | 0 | | | | | 5 | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Vzorek B | | 6,46 | 0,72 | 11 | 10 | | | | | | 10 | 9 | 90% | | | | | | | 0 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); | | 6,76 | 0,46 | 6,8 | 5 | 0 | CVPG | 6,35 | 0,068 | 21% | 5,01 | 7,69 | 5 | | | | | | | | | | |
| (60) Roche | | | | | | | | | | | | | | | | | | | | | | | |
| Ostatní | | | | | 5 | 0 | | | | | 5 | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |

st_kn_np

Konec sestavy

Vytiskeno: 21.05.2020